胰升糖素样肽1：非酒精性脂肪性肝病治疗的新靶点？

Glucagon-like peptide-1 ： New target for treating non-alcoholic fatty liver disease？

非酒精性脂肪性肝病（NAFLD）患者存在胰升糖素样肽1（GLP-1）信号受损。天然GLP-1或GLP-1类药物可通过GLP-1受体对肝细胞发挥直接作用，包括改善胰岛素抵抗、抑制氧化应激、调控脂代谢相关基因表达等。临床研究显示GLP-1类药物能够改善NAFLD患者的代谢指标和肝脏病变。

Recent studies have demonstrated an association of glucagon-like peptide-1 （ GLP-1 ） signaling defect with non-alcoholic fatty liver disease （NAFLD）. Native GLP-1 and GLP-l-based agents may directly act on hepatocytes through activation of GLP-1 receptors in hepatocytes, resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism, and the suppression of oxidative stress in liver cells. Moreover, GLP-1-based agents have been reported to be effective in improving hepatic endpoints in patients with NAFLD.